"Estrogen Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.
| Descriptor ID |
D004965
|
| MeSH Number(s) |
D06.347.295 D27.505.696.399.450.327
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Estrogen Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Estrogen Antagonists".
This graph shows the total number of publications written about "Estrogen Antagonists" by people in this website by year, and whether "Estrogen Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 4 | 1 | 5 |
| 1998 | 2 | 0 | 2 |
| 1999 | 2 | 1 | 3 |
| 2000 | 1 | 2 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 3 | 2 | 5 |
| 2012 | 0 | 2 | 2 |
| 2014 | 2 | 1 | 3 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 2 | 3 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Estrogen Antagonists" by people in Profiles.
-
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR?+?/HER2?-) advanced/metastatic breast cancer. Breast Cancer Res Treat. 2023 Jan; 197(2):319-331.
-
Elacestrant and the Promise of Oral SERDs. J Clin Oncol. 2022 10 01; 40(28):3227-3229.
-
The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. Mol Pharmacol. 2020 07; 98(1):24-37.
-
Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7.
-
Treatment of Estrogen Levels in the Management of Hypogonadism: An Anonymous Survey of ISSM Members. Urology. 2020 05; 139:104-109.
-
Effect of clomiphene citrate treatment on the Sertoli cells of dysmetabolic obese men with low testosterone levels. Clin Endocrinol (Oxf). 2020 01; 92(1):38-45.
-
Assessing research gaps and unmet needs in endometriosis. Am J Obstet Gynecol. 2019 08; 221(2):86-94.
-
Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2019 Apr; 174(2):297-305.
-
Testosterone Replacement Therapy Versus Clomiphene Citrate in the Young Hypogonadal Male. Eur Urol Focus. 2018 04; 4(3):321-323.
-
Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERa-GREB1 Transcriptional Axis. Cancer Res. 2018 02 01; 78(3):671-684.